372 related articles for article (PubMed ID: 31619483)
21. Characteristics of Patients With Late-Onset Pompe Disease in France: Insights From the French Pompe Registry in 2022.
Lefeuvre C; De Antonio M; Bouhour F; Tard C; Salort-Campana E; Lagrange E; Behin A; Sole G; Noury JB; Sacconi S; Magot A; Nadaj-Pakleza A; Lacour A; Beltran S; Spinazzi M; Cintas P; Renard D; Michaud M; Bedat-Millet AL; Prigent H; Taouagh N; Arrassi A; Hamroun D; Attarian S; Laforêt P;
Neurology; 2023 Aug; 101(9):e966-e977. PubMed ID: 37419682
[TBL] [Abstract][Full Text] [Related]
22. Sixty six-month follow-up of muscle power and respiratory function in a case with adult-type Pompe disease treated with enzyme replacement therapy.
Isayama R; Shiga K; Seo K; Azuma Y; Araki Y; Hamano A; Takezawa H; Kuriyama N; Takezawa N; Mizuno T; Nakagawa M
J Clin Neuromuscul Dis; 2014 Jun; 15(4):152-6. PubMed ID: 24872213
[TBL] [Abstract][Full Text] [Related]
23. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
24. Cardiopulmonary exercise test to quantify enzyme replacement response in pediatric Pompe disease.
Bar-Yoseph R; Mandel H; Mainzer G; Gur M; Tal G; Shalloufeh G; Bentur L
Pediatr Pulmonol; 2018 Mar; 53(3):366-373. PubMed ID: 29356433
[TBL] [Abstract][Full Text] [Related]
25. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
[TBL] [Abstract][Full Text] [Related]
26. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
Schoser B; Stewart A; Kanters S; Hamed A; Jansen J; Chan K; Karamouzian M; Toscano A
J Neurol; 2017 Apr; 264(4):621-630. PubMed ID: 27372449
[TBL] [Abstract][Full Text] [Related]
27. Pulmonary outcome measures in long-term survivors of infantile Pompe disease on enzyme replacement therapy: A case series.
ElMallah MK; Desai AK; Nading EB; DeArmey S; Kravitz RM; Kishnani PS
Pediatr Pulmonol; 2020 Mar; 55(3):674-681. PubMed ID: 31899940
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
[TBL] [Abstract][Full Text] [Related]
29. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.
Scheidegger O; Leupold D; Sauter R; Findling O; Rösler KM; Hundsberger T
J Neurol; 2018 Dec; 265(12):2783-2788. PubMed ID: 30232608
[TBL] [Abstract][Full Text] [Related]
30. Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study.
Deroma L; Guerra M; Sechi A; Ciana G; Cisilino G; Dardis A; Bembi B
Eur J Pediatr; 2014 Jun; 173(6):805-13. PubMed ID: 24395639
[TBL] [Abstract][Full Text] [Related]
31. Positive association between physical outcomes and patient-reported outcomes in late-onset Pompe disease: a cross sectional study.
Yuan M; Andrinopoulou ER; Kruijshaar ME; Lika A; Harlaar L; van der Ploeg AT; Rizopoulos D; van der Beek NAME
Orphanet J Rare Dis; 2020 Sep; 15(1):232. PubMed ID: 32883321
[TBL] [Abstract][Full Text] [Related]
32. Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.
Tard C; Bouhour F; Michaud M; Beltran S; Fournier M; Demurger F; Lagrange E; Nollet S; Sacconi S; Noury JB; Magot A; Cintas P; Renard D; Deibener-Kaminsky J; Lefeuvre C; Davion JB; Salort-Campana E; Arrassi A; Taouagh N; Spinazzi M; ; Attarian S; Laforêt P
Eur J Neurol; 2024 Jul; 31(7):e16292. PubMed ID: 38587143
[TBL] [Abstract][Full Text] [Related]
33. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
[TBL] [Abstract][Full Text] [Related]
34. Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients.
van den Dorpel JJA; Poelman E; Harlaar L; van Kooten HA; van der Giessen LJ; van Doorn PA; van der Ploeg AT; van den Hout JMP; van der Beek NAME
Orphanet J Rare Dis; 2020 Sep; 15(1):247. PubMed ID: 32928284
[TBL] [Abstract][Full Text] [Related]
35. Association between changes in pulmonary function and in patient reported outcomes during enzyme therapy of adult patients with late-onset Pompe disease.
Lika A; Andrinopoulou ER; van der Beek NAME; Rizopoulos D; van der Ploeg AT; Kruijshaar ME
J Inherit Metab Dis; 2023 Jul; 46(4):595-604. PubMed ID: 36966448
[TBL] [Abstract][Full Text] [Related]
36. Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease-a long-term follow-up.
Andreassen CS; Schlütter JM; Vissing J; Andersen H
Mol Genet Metab; 2014 May; 112(1):40-3. PubMed ID: 24685124
[TBL] [Abstract][Full Text] [Related]
37. [The long-term follow-up of enzyme replacement treatment in late onset Pompe disease].
Molnár MJ; Borsos B; Várdi KV; Grosz Z; Sebők Á; Dézsi L; Almássy Z; Kerényi L; Jobbágy Z; Jávor L; Bidló J
Ideggyogy Sz; 2020 May; 73(05-06):151-159. PubMed ID: 32579304
[TBL] [Abstract][Full Text] [Related]
38. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07).
Schoser B; Kishnani PS; Bratkovic D; Byrne BJ; Claeys KG; Díaz-Manera J; Laforêt P; Roberts M; Toscano A; van der Ploeg AT; Castelli J; Goldman M; Holdbrook F; Sitaraman Das S; Wasfi Y; Mozaffar T;
J Neurol; 2024 May; 271(5):2810-2823. PubMed ID: 38418563
[TBL] [Abstract][Full Text] [Related]
39. Enzymatic replacement therapy in patients with late-onset Pompe disease - 6-Year follow up.
Witkowski G; Konopko M; Rola R; Ługowska A; Ryglewicz D; Sienkiewicz-Jarosz H
Neurol Neurochir Pol; 2018 Aug; 52(4):465-469. PubMed ID: 29803406
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
